

Mr. Anvar Valiyevich Alimov The Minister of Health Ministry of Health Navoi Str. 12 700011 Tashkent Uzbekistan

10 June 2016

Decision Letter: Revision of Gavi-funded 2016 doses for Pneumococcal Vaccine

Dear Minister,

I am writing in relation to Uzbekistan's request for renewal of Pneumococcal Vaccine support which was approved by Gavi in October 2015 and communicated to the country through the Decision Letter dated 23 November 2015.

Following the country request to reduce the allocated doses, we have revised the volumes of the Gavi-supported portion and related injection safety materials for the year 2016. The previous approval for 2016 was for a total of 1,222,200 doses equivalent to US\$6,557,500. The revised approval is for 931,000 doses equivalent to US\$5,015,000. Kindly notice Uzbekistan's co-financing portion has been adjusted accordingly.

The attached Appendix A, replaces the Appendix A-1 provided to the Country on the 23 November 2015 Decision Letter, and provides the financial and programmatic information for this approval.

Please do not hesitate to contact my colleague Ms Nilgun Aydogan naydogan@gavi.org if you have any questions or concerns.

Yours sincerely,

Hind Khatib-Othman

Managing Director, Country Programmes

CC:

The Minister of Finance

Director Planning Unit, MoH

The EPI Manager

WHO Country Representative UNICEF Country Representative

Regional Working Group UNICEF Programme Division UNICEF Supply Division





Uzbekistan Support for Pneumococcal Vaccine This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Uzbekistan

2. Grant number: 16-UZB-12c-X

3. Date of Decision Letter: 10/06/2015

- 4. Date of the Partnership Framework Agreement: 07/02/2014
- 5. Programme title: New Vaccine Support (NVS), Pneumococcal Routine
- 6. Vaccine type: Pneumococcal
- 7. Requested product presentation and formulation of vaccine: Pneumococcal (PCV13), 1 dose(s) per vial, LIQUID
- 8. Programme duration¹: 2015 2016
- 9. Programme Budget (indicative): This is the amount endorsed by Gavi for the entire duration of the programme (subject to the terms of the partnership framework agreement)

Programme Year	2015	2016	Total
Programme Budget	US\$4,736,165	US\$5,015,000	US\$9,751,165
(US\$)			

- 10. Vaccine introduction grant (in US\$): Not applicable
- **11. Indicative Annual Amounts:** This is the amount Gavi has approved to be disbursed for programme year 2016 of implementation (subject to the terms of the partnership framework agreement)

Type of supplies to be purchased with Gavi funds in each year	2015	2016
Number of Pneumococcal vaccines doses		931,000
Number of AD syringes		1,272,000
Number of re-constitution syringes		
Number of safety boxes		14,025
Annual Amounts (US\$)	US\$4,736,165 ²	US\$5,015,000

- **12. Procurement agency:** UNICEF. The Country shall release its co-financing payments each year to UNICEF.
- 13. Self-procurement: Not applicable

¹ This is the entire duration of the Programme.

² This is the consolidated amount for all previously approved years.



14. Co-financing obligations: Reference code: 16-UZB-12c-X-C According to the co-financing policy, the Country falls within the group Accelerated transition.

The following table summarises the co-financing payment and quantity of supplies that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2016
Number of vaccine doses	369,000
Number of AD syringes	501,200
Number of re-constitution syringes	
Number of safety boxes	5,525
Value of vaccine doses (US\$)	US\$1,212,510
Total co-financing payments (US\$) (including freight)	US\$1,312,000

- 15. Operational support for campaigns: Not applicable
- 16. Additional reporting requirements: The Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future Annual Amounts.

Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum cofinancing levels and vaccines received.	May
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat

- 17. Financial clarifications: Not applicable
- **18. Other conditions:** The country is reminded of its obligations under the PFA in respect of insurance and is requested to provide information to Gavi on the steps it has taken in this regard.

Signed by,

On behalf of Gavi Hind Khatib-Othman

Managing Director, Country Programmes

10 June 2016